ArticleFrontiers in reproductive health2025
Evaluation of a low-intensity pulsed ultrasound for chronic prostatitis type IIIb/chronic pelvic pain syndrome: a randomized controlled trial.
Article in Frontiers in reproductive health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic prostatitis type IIIb/chronic pelvic pain syndrome (CP/CPPS) poses significant therapeutic challenges. This study aimed to investigate and compare the clinical efficacy and safety of low-intensity pulsed ultrasound (LIPUS) versus tamsulosin for treating CP/CPPS. Methods: In this randomized controlled trial, 65 patients with CP/CPPS were allocated to two groups. Group A ( Results: After 4 weeks, both groups showed significant improvements in all NIH-CPSI domains (pain, urinary, quality of life), SAS, and IIEF-5 scores compared to baseline (all Conclusion: Both LIPUS and tamsulosin significantly alleviated CP/CPPS-related symptoms with a favorable safety profile. LIPUS was more effective for pain relief, while tamsulosin was superior for urinary symptoms. Combination therapy may represent a promising approach for managing CP/CPPS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.